Although antibodies against the third variable loop (V3) of the HIV-1 viral envelope glycoprotein are among the first neutralizing antibodies to be detected in infected individuals, they are normally restricted in their specificity. X-ray crystallographic studies of V3-specific antibodies have contributed to a more thorough understanding of recognition of this epitope and of conserved features in the V3 loop that could potentially aid in the design of a multi-component vaccine. The human antibody 447-52D exhibits relatively broad neutralization of primary viral isolates compared with other V3-loop antibodies. A crystal structure of Fab 447-52D in complex with a V3 peptide (UG1033) was determined at 2.1 Å resolution. The structure was determined using an epitaxially twinned data set and in-house programs to detect and remove overlapping reflections. Although the processed data have lower than desired completeness and slightly higher than normal R values for the resolution, good-quality electron-density maps were obtained that enabled structure determination. The structure revealed an extended CDR H3 loop that forms a -sheet with the peptide, with the predominant contacts being main-chain hydrogen bonds. The V3 peptide and Fab show high structural homology with the previously reported structures of other Fab 447-52D complexes, reinforcing the idea that the V3 loop may adopt a small set of conserved structures, particularly around the crown of the -hairpin.
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Introduction
The human immunodeficiency virus type 1 (HIV-1) envelope is a highly glycosylated trimer of heterodimers, composed of gp120, which mediates binding to the cell-surface CD4 receptor and chemokine co-receptors, and gp41, a transmembrane protein that is involved in membrane fusion. Despite its exposure on the viral surface, the HIV-1 envelope spike, which is the target of neutralizing antibodies, has evolved many diverse mechanisms to escape the humoral immune response. Extensive glycosylation of the exposed envelope protein, which gives rise to an immunologically silent 'glycan shield', and exposure of regions of gp120 that are highly variable in sequence, termed the V1-V5 hypervariable loops, are among the major mechanisms that contribute to the ability of HIV-1 to evade the antibody response during infection (Burton et al., 2005; Pantophlet & Burton, 2006; Wei et al., 2003; Wyatt et al., 1998) . The glycan shield results in a general dampening of the immune response, whereas the immunodominant variable loops tend to elicit neutralizing antibodies that exhibit strain-specific neutralization.
The third hypervariable (V3) loop of gp120 was initially known as the principal neutralizing determinant of HIV-1 owing to its ability to readily elicit anti-HIV-1 antibodies (Gao et al., 2005; Goudsmit et al., 1988; Javaherian et al., 1989 Javaherian et al., , 1990 Rusche et al., 1988) . The anti-V3 antibodies induced early in infection and after limited exposure to immunogens are relatively type-specific; however, anti-V3 antibodies that display broader reactivity have been reported (Binley et al., 2004; Gorny et al., 2002 Gorny et al., , 2006 Krachmarov et al., 2005; Pantophlet et al., 2007; Richman et al., 2003) . The neutralization activity of anti-V3 antibodies may be affected by the propensity of the V3 region to undergo sequence changes that alter neutralizing-antibody epitopes and give rise to escape mutants during the course of infection (Hartley et al., 2005; Richman et al., 2003) , epitope masking by the V1/V2 domain (Hartley et al., 2005; Pantophlet & Burton, 2006; Pinter et al., 2004) and/or the presence of glycans (Back et al., 1994; Koch et al., 2003; McCaffrey et al., 2004) .
However, human V3-specific monoclonal antibodies (mAbs) have been described that exhibit neutralization of multiple primary HIV-1 isolates, suggesting that this region may indeed be a worthwhile target in a multi-component HIV-1 vaccine. The antibody 447-52D, which was originally isolated from an HIV-1-infected individual (Gorny et al., 1992 (Gorny et al., , 1993 , is one of several anti-V3 monoclonal antibodies ) that exhibit significant neutralizing breadth (Binley et al., 2004) . Immunochemical studies mapped the core epitope to a GPxR motif in the crown of the V3 loop (Keller et al., 1993) . Although this motif is prevalent within subtype B isolates, the dominant crown motif of non-clade-B isolates is GPGQ (http://www.hiv.lanl.gov/content/hiv-db). In one analysis, Fab 447-52D neutralized 50% of 32 clade-B viruses (Binley et al., 2004) ; in a second study, 92% of 38 primary isolates containing the GPGR crown motif could be neutralized . The V3-specific mAb 2219, which was also derived from an HIV-1-infected individual, similarly exhibits neutralization of a relatively large proportion of HIV-1 isolates (Gorny et al., 2002 . More recently, human mAb F425-B4e8 has been reported to exhibit crossneutralizing activity comparable to those of Fab 447-52D and Fab 2219 (Pantophlet et al., 2007) .
In addition to being a potential target for a neutralizing epitope in an HIV-1 vaccine, the V3 loop plays an important role in virus infectivity. The sequence of the V3 loop can influence cell tropism (Hoffman & Doms, 1999 ) and this loop is thought to interact with the chemokine co-receptors CCR5 or CXCR4 during infection (Basmaciogullari et al., 2002; Rizzuto & Sodroski, 2000; Rizzuto et al., 1998) . The V3 region is composed of approximately 35 residues and contains a conserved disulfide bridge at the base of the loop. A recent crystal structure of an HIV-1 gp120 core containing an intact V3 loop reveals that this region contains three structurally distinct domains: a conserved base, a crown or tip region (apex) and a flexible stem that links the base and crown (Huang et al., 2005) . Antibody-binding studies performed in the presence of soluble CD4 suggest that the V3 loop may become more accessible upon CD4 binding (Mbah et al., 2001) . Such an extended structure could help to explain the immunodominance of the V3 loop. Cryo-electron tomography studies performed with SIV virions suggest two possible models for the location of the V3 loop within the context of the trimeric envelope. In the first, the V3 loop is solventexposed and positioned away from the trimer interface along the outer side of gp120 (Zhu et al., 2006) . Alternatively, the V3 region may be packed into the trimer interface and become exposed upon CD4-envelope ligation owing to structural rearrangement of the trimer (Zanetti et al., 2006) .
To gain a better understanding of the conformation of the V3 loop and of the basis for neutralization by V3 mAbs, structural studies of anti-V3 mAbs in complex with V3 peptides have been undertaken. To date, X-ray crystallographic structures of four murine anti-V3 Fabs (50.1, 58.2, 59.1, 83.1) have been determined for the Fabs in complex with V3 peptides corresponding to the HIV-1 isolate MN (Ghiara et al., 1994 (Ghiara et al., , 1997 Rini et al., 1993; Stanfield et al., 1993 Stanfield et al., , 1999 Stanfield et al., , 2003 . The crystal structure of human Fab 447-52D has also been determined in complex with an MN peptide (Stanfield et al., 2004) Gorny et al., 2006) . The MN V3 peptide adopts a similar conformation in complex with the murine Fabs 50.1, 59.1 and 83.1, whereas a different V3-crown structure is observed in the Fab 58.2 complex. In the former, residues upstream of the crown form an extended -sheet, with a type I or II -turn around the GPGR crown motif. The V3 peptide in the Fab 58.2 complex adopts a different conformation at the crown that contains two consecutive turns. The V3 peptides in the Fab 447-52D and Fab 2219 crystal structures show structural homology to these murine Fab complexes, adopting -hairpin structures, although the relative orientation of the N-and C-terminal strands in the Fab 2219 peptides differs owing to a differing torsion angle of a single residue within the N-terminal strand. These V3 structures are also comparable to the conformation observed in the V3-containing core gp120 structures (Huang et al., 2005 (Huang et al., , 2007 . Finally, NMR studies of the Fv fragment of 447-52D in complex with V3 peptides corresponding to isolates MN and IIIb show that the peptides in both of these complexes form -hairpin structures and exhibit the same N-terminal conformation (Rosen et al., 2005; Sharon et al., 2003) .
Here, we report the processing strategy for an epitaxially twinned data set (Table 1 ) and the details of the resulting 2.1 Å structure of the UG1033 V3 peptide bound to Fab 447-52D. We also discuss insights gained from a comparative analysis of this new structure with those previously reported for other V3-peptide complexes of Fab 447-52D.
Experimental

Fab production and purification
IgG 447-52D (IgG3, ) was produced and purified as previously reported (Gorny et al., 1989 (Gorny et al., , 1991 . Briefly, pooled peripheral blood cells from two HIV-1-infected patients were transformed and fused to a human/mouse hetero-myeloma cell line (SHM-D33). The Mab 447-52D heterohybridoma was selected based on its ability to bind a peptide corresponding to a portion of the V3 sequence of the HIV-1 isolate MN (YN-KRKRIGIGPGRAFYTTKNIIG) and then repeatedly cloned until monoclonality was achieved. Fab fragments were prepared by IgG 447-52D cleavage with 4% papain in 10 mM l-cysteine for 4 h. Fab 447-52D was purified on Protein A, Superdex 200 (10/30 column; 0.2 M sodium acetate pH 5.5) and Mono S columns (10/10 column; buffer A = 50 mM sodium acetate pH 4.5; buffer B = 50 mM sodium acetate, 1 M sodium chloride pH 4.5).
Crystallization
A 23-mer V3 peptide, UG1033 (NNTRKSIHLGP-GRAFYATGDIIG), was used for cocrystallization. Fab 447-52D (20 mg ml À1 ) and UG1033 peptide were mixed in a 1:5 molar ratio and crystals were grown using the standard sittingdrop vapor-diffusion method. Thin intergrown crystal plates which could not be readily separated were grown from 1.4 M ammonium sulfate, 0.1 M cacodylate pH 6.5 and did not diffract beyond 2.5 Å . However, screening of these conditions with Hampton Additive Screen 1 revealed larger single-crystal plates with CuCl 2 as an additive. Crystals that visually appeared to be single were grown using a final reservoir solution of 1.58 M ammonium sulfate, 0.1 M Tris pH 7.88, 1 mM CuCl 2 . Crystals were cryopreserved by brief immersion into a solution consisting of the reservoir solution augmented with 25% glycerol. Data were collected to 2.1 Å resolution on SSRL beamline 11-1 with a 0.25 step size and a crystal-todetector distance of 250 mm on an ADSC Q315 detector and reduced in space group P2 1 with unit-cell parameters a = 70.5, b = 75.9, c = 114.1 Å , = 101.5
. The Matthews coefficient was 3.0 Å 3 Da À1 (Matthews, 1985) , corresponding to 59% solvent content. Data were indexed, integrated and scaled with HKL-2000 (Otwinowski & Minor, 1997) to 2.1 Å resolution (Table 2) . Multiple lattices were detected in all crystals that were screened. Twinned data sets were resolved using DENZO/SCALEPACK (Otwinowski & Minor, 1997) and inhouse programs, as described below in x3. Table 2 Processing and final refinement statistics for data set 6. 
Structural determination and refinement
The structure was determined by molecular replacement using the refined structure of Fab 447-52D (PDB code 1q1j) as a search model. Two Fab-peptide complexes were present in the asymmetric unit and were related by an NCS twofold around x (or z). Alternating cycles of model building and positional refinement were carried out using TOM/FRODO (Jones, 1982) and CNS (Brü nger et al., 1998). Tight NCS restraints were used early in refinement and then gradually released. Final rounds of refinement were carried out using REFMAC (Collaborative Computational Project, Number 4, 1994) with eight TLS groups corresponding to C L , V L , C H 1 and V H + peptide for each Fab complex. B values for all protein domains and solvent molecules are reported in Table 2 . An R free test set of 5% of the reflections was maintained throughout refinement. Electron-density maps used for rebuilding included A -weighted 2F o À F c and F o À F c maps. Hydrogen bonds and van der Waals contacts were evaluated with HBPLUS (McDonald & Thornton, 1994) and CONTACSYM (Sheriff et al., 1987) . Buried molecular-surface areas were calculated using the program MS (Connolly, 1993) with a 1.4 Å probe radius.
Results and discussion
Lattice separation in the epitaxially twinned crystals
Although the crystals grown in the presence of CuCl 2 diffracted strongly, they contained two separate lattices of approximately equivalent intensity with the same unit-cell parameters, as if two crystals in different orientations had intergrown (Fig. 1 ). Multiple crystals were tested, but none were obtained with a single lattice. Attempts to obtain strongly diffracting crystals under alternative growth conditions also failed. As a result, data from the epitaxially twinned crystals were collected and processed with DENZO/SCALE-PACK (Otwinowski & Minor, 1997) and in-house programs, as detailed below, to include data from both lattices. While published descriptions of computer programs for treating epitaxially twinned data processed with XDS (Lietzke et al., 1996) and XENGEN (Schulze-Gahmen et al., 1993) are available, we were unable to find any similar programs that worked with DENZO/SCALEPACK. Since this work was carried out, a web-based server has been developed in another laboratory that works with DENZO/SCALEPACK using a similar scheme to that which we describe here (http://ultr23.-vub.ac.be/untangle).
Firstly, a standard DENZO/XDISP peak search was used to find spots on the first diffraction image. The term 'spots' will be used throughout to define two-dimensional diffraction peaks from a single image that result, in most cases, from partial reflections. The spots representing both lattices were used in the initial DENZO autoindexing. The autoindexing routine then calculates a unit cell and orientation matrix for one of the two lattices and using this information 'spots' from 'lattice 1' only were integrated. An in-house program was then used to compare the x, y centroid position of each integrated spot from lattice 1 with the spot positions found by XDISP. The XDISP spots were then separated into two files, one containing the spots within two pixels (1 pixel = 0.1024 mm) of integrated spots from lattice 1 and a second file containing the remaining spots, which predominantly belong to lattice 2 (Fig. 1) . Each of these XDISP spot files was used as input to the autoindexing routine in DENZO, resulting in a unit cell and orientation matrix for each lattice. All frames were then integrated twice, once with each orientation matrix, resulting in files containing integrated spots from each of the two lattices. The two lattices are related by an approximate twofold rotation around the c axis of the crystal.
To deal with the problem of overlapping spots that arise from both lattices, another program was written to read in the files containing the integrated spots for each lattice on a frame-by-frame basis and then delete spots whose predicted centroid positions (in pixel units) are within two pixels (1 pixel = 0.1024 mm) of each other. The partial spots were then summed and profile-fitted to create the integrated intensities (observations) and scaled using SCALEPACK (to obtain unique reflections) for each of the individual lattices and also for the merged lattices (lattice 1 + 2) with and without overlapping-spot deletion. We generated six data sets using these criteria (see Table 1 ) in order to evaluate the best method for treating these data. Two to three rounds of initial model refinement with CNS were then carried out with each data set to determine which would yield the best quality model, as judged by R values and stereochemistry. Structures could be readily refined with all six data sets (see x2) with electrondensity maps of similar quality. The R cryst and R free values are also very similar (Table 1 ). The final structure reported here was determined at 2.1 Å from the sixth data set in Table 1 , which was chosen because it had the lowest R cryst /R free values of the six data sets. The final statistics listed in Table 2 are for the sixth data set, but with model rebuilding and complete refinement in addition to the preliminary refinements reported for the initial tests of the six data sets in Table 1 .
Structure of Fab 447-52D
Fab 447-52D was crystallized with a 23-mer V3 peptide designated UG1033 (NNTRKSIHLGPGRAFYATGDIIG). Processing and refinement statistics for the 2.1 Å structure are reported in Table 2 . The crystallographic asymmetric unit contains two Fab complexes related by a noncrystallographic (NCS) twofold axis around x (or z). Slightly higher B values and weaker electron density were observed in the second Fab complex, indicating a higher degree of flexibility for this complex. The C r.m.s. deviations for the equivalent variable light-chain (V L ) and heavy-chain (V H ) regions are 0.31 and 0.22 Å , respectively, and 0.43 Å for the V3 peptide. Because the two structures are so similar, only the first of the two molecules is discussed here unless noted otherwise. The Fab chains are numbered according to the Kabat and Wu convention (Kabat et al., 1987) and the peptide is numbered according to the HIV-1 HxBc2 numbering convention (Ratner et al., 1987 is in a loop which also has well ordered density. One residue, Ser H134 , lies within the generously allowed region of the Ramachandran plot and is within in a poorly ordered region of C H 1 that tends to be disordered in most Fabs. Although CuCl 2 was part of the crystallization solution, no density was found that could be assigned to copper or chloride ions. An overview of the Fab 447-52D structure is illustrated in Fig. 2 . As expected based on length and sequence, the light-chain CDR1 and CDR2 belong to canonical classes L1-1 and L2-2 and the heavy-chain CDR1 and CD2 to classes 1 and 4, respectively. As reported previously, the light-chain CDR3 of Fab 447-52D contains a three-residue insertion (L95a-L95c) that makes it longer than other CDR L3 loops classified to date (Stanfield et al., 2004) . The 20-residue heavy-chain CDR3 (H3) forms an extended structure, approximately 32 Å from base to tip, which projects outwards from the molecule. The extended structure is stabilized by a hydrogen-bonding network between the N-and C-terminal regions of the CDR H3 loop.
Structure of the UG1033 V3 peptide
The majority of clade A and C isolates contain the V3-crown sequence GPGQ. However, the clade A UG1033 sequence corresponds to the dominant crown motif, GPGR, typically found in clade B. Although the UG1033 peptide is 23 residues in length, strong interpretable electron density was only present for ten residues (Fig. 3) . Weaker electron density was present for an additional three residues (Phe P317 , Tyr P318 and Ala P319 ), which are also included in the final model. The remaining C-terminal residues could not be built into the final model owing to very weak electron density, which is likely to be a consequence of the conformational flexibility of this region of the peptide, as frequently observed in other V3-loop complexes with Fabs (Ghiara et al., 1994 (Ghiara et al., , 1997 Rini et al., 1993; Stanfield et al., 1993 Stanfield et al., , 1999 Stanfield et al., , 2003 Stanfield et al., , 2004 Stanfield, Gorny et al., 2006) . The V3 peptide binds alongside the extended CDR H3 (Fig. 2) , forming a threestranded mixed -sheet with CDR H3 (Fig. 4a) . The majority of contacts between the Fab and peptide are main-chain hydrogen bonds between the N-terminal half of the peptide and the C-terminal portion of the CDR H3 (Fig. 4b) (Fig. 4c) . The conserved V3-crown motif, GPGR, forms a type II -turn (' i+1 = À71 , i+1 = 138 for Pro
P313
, ' i+2 = 78 , i+2 = 2 for Gly P314 ), as previously observed in the Fab 447-52D in complex with an MN V3 peptide (Stanfield et al., 2004) .
110 and 141 van der Waals interactions are made in the two Fab-peptide complexes, respectively. The buried molecularsurface areas of the Fab and peptide are 553/587 and 522/ 487 Å 2 for the two Fab-peptide complexes. The buried surface area of the Fab is largely formed by aromatic tyrosine and tryptophan residues (69%/65%), followed by acidic (19%/ 20%), basic (6.4%/6.2%), polar (2.4%/4.1%) and small and/or hydrophobic residues (3.3%/4.9%).
Comparison with the Fab 447-52D-MN V3-peptide complex
Only minor differences are observed between the structure of the Fab 447-52D complex reported above and the Fab 447-52D-MN V3 peptide complex previously reported by our group (Stanfield et al., 2004 ) based on comparisons calculated using the first molecule of the asymmetric unit of each crystal structure. When the most highly ordered residues in the peptides are superimposed (Lys n/a 170 À2 † Torsion angles were calculated from the structure with PDB code 2b1a. ‡ Torsion angles are those reported by Stanfield, Gorny et al. (2006) from analysis of the structure with PDB code 2b4c (Huang et al., 2005) . for the extra three residues is weak. In the UG1033 V3-peptide structure, Tyr P318 contacts a symmetry-related Lys
L156
in the second molecule in the asymmetric unit, but not in the first molecule. This contact is not made in the MN V3-peptide complex owing to a slight difference in the packing of the molecules. It is not clear whether this contact has helped to stabilize these residues or whether the stronger peptide density is a function of the better diffraction of the UG1033 V3-peptide complex crystals. The GPGR crown motif also adopts a type II -turn in each of the two structures. The two different Fab 447-52D structures also do not differ significantly, with C backbone r.m.s.d. values of 0.24 Å for the V L domain and 0.34 Å for the V H domain. Notably, inclusion of an additional three residues in the C-terminal portion of the UG1033 peptide also does not increase the peptide-binding interactions with Fab 447-52D.
The UG1033 V3-peptide sequence differs from the MN peptide at two positions. An arginine is present at position P306 and an isoleucine at position P309 in the MN peptide, whereas serine and leucine are found in these positions, respectively, in the UG1033 peptide. However, as expected, these differences in sequence do not affect the main-chain hydrogen bonds that the peptide forms with Fab 447-52D CDR H3. Although P317-P319 at the C-terminus of the UG1033 peptide do not interact with the Fab, they contact the N-terminal strand of the V3 peptide through main-chain hydrogen bonds to form a more regular -hairpin-type structure. An evaluation of hydrogen-bond contacts detects additional hydrogen bonds in each peptide between Phe P317 O and His P308 N (2.8/2.6 Å ) and a second hydrogen bond in the second peptide between Ala Q319 N and Ser Q306 O (2.7 Å ). The distance between Ala P319 N and Ser P306 O increases slightly in the first peptide to 3.1 Å , although the density at the C-terminus is weaker.
Comparison with Fab 2219-UG1033 and gp120 V3 core structures
The UG1033 peptide structure has also been determined in complex with the V3-specific Fab 2219 (Stanfield, Gorny et al., 2006) . As observed here, the GPGR motif also forms a type II -turn in the Fab 2219 structure, with a C r.m.s.d. of 0.21 Å to the Fab 447-52D structure (Gly P312 -Arg
P315
). However, a difference in one of the dihedral angles ( ) of Leu P309 results in a change in the orientation of the peptide backbone (Table 3) . Hence, the carbonyl O atoms of the N-terminal residues preceding Leu P309 are rotated by about 180 in the Fab 2219 complex with respect to the conformation seen in the Fab 447-52D complex (Fig. 6 ). Despite this difference, the Nand C-terminal strands of the hairpin independently show close structural homology with the UG1033 peptide in the Fab 447-52D structure, with C backbone r.m. -Ala P319 ). When bound to Fab 2219, the majority of contacts are made through side chains of residues in the N-terminal strand of the UG1033 peptide, although two side-chain contacts from C-terminal residues are also observed. Despite making contact with the Fab 2219, N-terminal residues Thr P303 -Ser P306 are still solvent-exposed. It is likely that Fab 2219 is able to tolerate diversity in side chains at these positions because of the solvent-accessible nature of these residues. In contrast, the use of main-chain hydrogen-bond contacts allows Fab 447-52D to tolerate diversity within the N-terminal region of the V3. In both structures, Arg P315 makes side-chain contacts with the Fab and forms salt bridges to Asn L31 in Fab 2219 and to Asp H95 in Fab 447-52D. However, the UG1033 V3 crown is also largely accessible in the Fab 2219 complex, whereas it is less accessible and oriented into the antibody-binding pocket in the Fab 447-52D complex reported here. The structure of the UG1033 V3 peptide in the Fab 447-52D complex also reveals structural homology to the V3 region of gp120-containing V3 crystal structures (Fig. 6 ). The C backbone r.m.s.d. values of the UG1033 peptide with the corresponding V3 loop in the reported gp120 V3 structure (Huang et al., 2005) ) and C-terminal (Ala P316 -Ala P319 ) strands respectively, and 0.59 Å for the GPGR crown motif. A gp120-containing V3 structure in complex with a tyrosine-sulfated antibody has recently been reported (Huang et al., 2007) . The GPGR crown of the V3 loop in this structure exhibits even greater structural homology with the crown of the UG1033 V3 peptide, with a C backbone r.m.s.d. value of only 0.16 Å .
Comparison with NMR structures
The structures of MN and IIIB V3 peptides in complex with 447-52D Fv have also been determined by NMR methods. Solution (Sharon et al., 2003) and solid-state (Sharpe et al., 2004) 52D Fv show an overall similarity to the structure reported here (Fig. 7) with an inverse -turn at the crown. The extended C-terminal portion of the -hairpin is not observed here, which is likely to be the consequence of flexibility of the C-terminal residues in the UG1033 peptide. However, the overall shape of the peptides is similar (Fig. 7) , with a C r.m.s. (Rosen et al., 2005) . The V3 loop of HIV-1 IIIB contains a two-residue insertion (QR) before the GPGR crown sequence. In the IIIB V3-Fv structure the peptide forms a -hairpin, although the QR insertion creates a kink before the -turn at the crown. Despite the two-residue insertion, the resulting structure is very similar to the UG1033 crystal structure and the MN NMR structure (Fig. 7) Comparison of the crystal structure of the UG1033 peptide bound to Fab 447-52D with the NMR structures of the MN and IIIB peptides bound to 447-52D Fv. The C -backbone structures are shown in a similar orientation for (a) the UG1033 V3 peptide from the crystal structure and (b) MN (PDB code 1n1z) and (c) IIIB (PDB code 1u6u) from NMR structures. The N-terminus of each peptide is oriented to the left.
Figure 6
Comparison of V3 crystal structures. The C -backbone structures are shown in a similar orientations for (a) the UG1033 V3 peptide bound to Fab 447-52D (b) the UG1033 V3 peptide bound to Fab 2219 (PDB code 2b1a) and the V3 loops from two gp120 core complexes: (c) PDB code 2b4c and (d) PDB code 2qad. Two conformations were observed for the V3 crown in the core gp120 V3 structure with PDB code 2b4c and both of these conformations are shown in (c . These aromatic contacts are not identical to those proposed in the IIIB-447-52D Fv NMR structure. However, as previously suggested (Rosen et al., 2005) , the QR insertion in the IIIB peptide may alter the positioning of the peptide in the 447-52D binding site.
Conclusions
The structure of the UG1033 peptide in complex with Fab 447-52D has been determined from an epitaxially twinned data set where the individual lattices were separated and overlapping reflections were removed. The final R cryst and R free values of the model are higher than expected at this resolution, which is likely to be the consequence of some residual overlapping spots (diffraction maxima) that were not removed by the procedure. However, given the quality and resolution of the electron-density maps, the Fab-peptide complex can still be determined with confidence. Moreover, this structure shows very high structural homology to the crystal structure of the MN V3 peptide in complex with Fab 447-52D previously reported by our group (Ghiara et al., 1994 (Ghiara et al., , 1997 Rini et al., 1993; Stanfield et al., 1993 Stanfield et al., , 1999 Stanfield et al., , 2003 Stanfield et al., , 2004 and to the NMR structure (Sharon et al., 2003) , further validating the final model built from the epitaxially twinned data set.
The structure of the Fab 447-52D complex reported here confirms our previous conclusion that the breadth of this neutralizing antibody is attributable to the use of main-chain hydrogen bonds to contact the N-terminal region of the V3-loop backbone (Stanfield et al., 2004) . This mode of antigen recognition enables 447-52D to bind a diverse range of V3 sequences. We observe here that a two-residue sequence difference between the UG1033 peptide and the MN peptide previously determined in complex with Fab 447-52D (Arg  P306 -Ser  P306 and Ile   P309 -Leu P309 ) does not alter the binding interactions between the V3 peptides and Fab. The reported dependence of antigen recognition on the presence of the conserved crown motif GPxR (Keller et al., 1993) can be explained in part by the observation that the crown and in particular Arg P315 form specific interactions with the antibodybinding site. Finally, the V3-peptide structure shows a high level of structural homology with previously reported V3 crystal and NMR structures, supporting the hypothesis that the V3 loop of gp120 may adopt a conserved structure or limited set of structures, particularly at the crown (ZollaPazner, 2004; Ghiara et al., 1994 Ghiara et al., , 1997 Rini et al., 1993; Stanfield et al., 1993 Stanfield et al., , 1999 Stanfield et al., , 2003 Stanfield et al., , 2004 Stanfield, Gorny et al., 2006; Cardozo et al., 2007; Rosen et al., 2006) . Future structural studies of such V3-specific neutralizing antibodies in complex with a diverse range of V3 peptides will help to further clarify conserved structural features of the V3 loop, as well as the precise mechanism by which V3 antibodies recognize their epitopes. This information will in turn provide valuable insight into how the V3 region of gp120 may be utilized as an anti-HIV-1 immunogen that may provide some efficacy in combination with immunogens corresponding to other epitopes.
